The article focuses on investigating the contribution of AGE/RAGE (advanced glycation end products/receptor of AGEs) and senescence pathways in the context of inflammatory bowel disease (IBD) and highlights the potential of PPAR-γ activation, particularly with GED (PPAR-gamma-agonist).